Triplet Therapy in Metastatic Castrate Sensitive Prostate Cancer (mCSPC)—A Potential New Standard of Care

The treatment paradigm for metastatic castrate-sensitive prostate cancer (mCSPC) has evolved rapidly in the past decade with the approval of several life-prolonging therapies including docetaxel chemotherapy and multiple androgen receptor pathway inhibitors (ARPI) in combination with androgen depriv...

Descripción completa

Detalles Bibliográficos

Autores principales:	Abhenil Mittal, Srikala S. Sridhar, Michael Ong, Di Maria Jiang
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	MDPI AG 2023-04-01
Colección:	Current Oncology
Materias:	metastatic castrate sensitive prostate cancer triplet therapy androgen receptor pathway inhibitors docetaxel abiraterone darolutamide
Acceso en línea:	https://www.mdpi.com/1718-7729/30/4/332
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!